Survival To Discharge Among Cardiogenic Shock Patients Supported By VA-ECMO: An Insight From The Largest VA-ECMO Experience In The Middle East-Gulf Region
Guirgis Gabra,Yosef Manla,Firas Al Badarin,Hussam Ghalib,Vivek Kakar,Praveen Ghisulal,Obada Kholoki,Nadya Almatrooshi,Medhat Soliman,Iman Mukhtar Hamour,Walid El Tahlawy,Shahrukh Hashmani,Shady Abdelsayed,Mitesh Badiwala,Feras Bader
DOI: https://doi.org/10.1016/j.cardfail.2023.10.131
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Background Mortality among patients with cardiogenic shock remains high. Despite the increasing use of veno-arterial extracorporeal membranous oxygenation (VA-ECMO) to support patients with cardiogenic shock, in-hospital mortality remains unacceptably high. Optimizing VA-ECMO outcomes rests on identifying patients likely to derive survival advantages from this resource-intensive treatment, especially in nascent programs. Therefore, we aimed to describe patient characteristics and clinical outcomes in a single-center experience in the Middle East. Methods Patients who received VA-ECMO support (12/2016 to 01/2023) at a quaternary care center in the Middle East were retrospectively identified using electronic health records. Baseline characteristics, use of vasopressors, invasive hemodynamic monitoring, systemic complications, and clinical outcomes were compared between survivors vs. non-survivors at hospital discharge using appropriate testing. Outcomes of interest included successful weaning, need for 2nd ECMO run during index admission, use of advanced heart failure therapies, in-hospital stroke, bleeding, or death. Results A total of 110 unique patients received VA-ECMO support (49.4 ± 15.3 years, 67.3% males). The most common indications for initiation of ECMO were advanced heart failure (30.9%), post-cardiotomy (23.6%), and post-cardiac arrest (20.0%). A multidisciplinary heart failure team was involved in VA-ECMO initiation/ weaning and active management of vasoactive medications in 59 (53.6%) of the patients. Although 51.4% of the patients were successfully weaned off ECMO and 5.5% were bridged to advanced therapies, only 31.8% overall survived to hospital discharge, and 10.0% required a second run of VA-ECMO support. Post-ECMO complications were common, with 41.1% incidence of sepsis, 43.5% bleeding and 18.7% stroke. Compared to non-survivors, the survivors were younger, had lower BMI, and were less likely to have diabetes and hypertension (Table). Conclusion In hospitalized patients requiring VA-ECMO support, risk of in-hospital mortality and morbidity remains high. Identifying patient characteristics associated with survival and expanding involvement of ‘shock teams’ in care of these patients will likely improve patient selection and outcomes in this challenging population.
cardiac & cardiovascular systems